RhumbLine Advisers’s SpyGlass Pharma SGP Stock Holding History

RhumbLine Advisers’s Portfolio SGP Stock Details SGP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$264K	Buy	+11,844	New	+$257K	﹤0.01%	3145

Other funds holding SGP

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

RhumbLine Advisers's SGP Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in SpyGlass Pharma (SGP) in Q2 2026: 11,844 shares worth $264K. The stake represents ﹤0.01% of the portfolio and ranks #3145 among its holdings.

43 funds tracked by Wall St. Rank hold SGP as of Q2 2026.

RhumbLine Advisers held 11,844 shares of SpyGlass Pharma worth $264K as of Q2 2026.
SpyGlass Pharma was a new RhumbLine Advisers position in Q2 2026.
SpyGlass Pharma made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3145 holding.
43 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.